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Abstract
Objective: The aim of this study was to examine the association between ectopic fat and organ-specific insulin resistance
(IR) in insulin-target organs in patients with nonalcoholic fatty liver disease (NAFLD).
Methods: Organ-specific IR in the liver (hepatic glucose production (HGP)6fasting plasma insulin (FPI) and suppression of
HGP by insulin [%HGP]), skeletal muscle (insulin-stimulated glucose disposal [Rd]), and adipose tissue (suppression of FFA by
insulin [%FFA]) was measured in 69 patients with NAFLD using a euglycemic hyperinsulinemic clamp with tracer infusion
([6,6-2H2]glucose). Liver fat, intramyocellular lipid (IMCL), and body composition were measured by liver biopsy, proton
magnetic resonance spectroscopy, and bioelectrical impedance analysis, respectively.
Results: HGP6FPI was significantly correlated with Rd (r=20.57, P,0.001), %HGP with %FFA (r= 0.38, P,0.01), and Rd with
%FFA (r= 0.27, P,0.05). Liver steatosis score was negatively associated with Rd (r=20.47, P,0.001) as well as with
HGP6FPI (r = 0.43, P,0.001). Similarly, intrahepatic lipid was negatively associated with Rd (r=20.32, P,0.05). IMCL was not
associated with Rd (r=20.16, P= 0.26). Fat mass and its percentage were associated with HGP6FPI (r = 0.50, P,0.001;
r = 0.48, P,0.001, respectively) and Rd (r=20.59, P,0.001; r=20.52, P,0.001, respectively), but not with %FFA (r=20.21,
P= 0.10; r=20.001, P= 0.99, respectively).
Conclusion: Unexpectedly, fat accumulation in the skeletal muscle and adipose tissue was not associated with organ-
specific IR. Instead, liver fat was associated not only with hepatic IR but also with skeletal muscle IR, suggesting a central role
of fatty liver in systemic IR and that a network exists between liver and skeletal muscle.
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Introduction
Insulin resistance (IR) is a core pathology of type 2 diabetes
mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), and
cardiovascular diseases [1–3]. The severity of IR may differ among
the major insulin-target organs, the liver, skeletal muscle, and
adipose tissue [4]. Accumulating evidence suggests that ectopic fat
accumulation in insulin-target organs leads to development of IR
in each organ by altering oxidative stress [5–7] and gene
expression profiles [8,9]. Indeed, liver steatosis is associated with
whole-body IR, independently of body mass index (BMI) [10].
Conversely, inter-organ network and organ-derived bioactive
hormones such as adiponectin and selenoprotein P may play a role
in the development of distant organ IR [11–13]. Therefore, to
understand organ networks that sense excess energy and regulate
insulin action, elucidating the association between fat accumula-
tion and organ-specific IR among the liver, skeletal muscle, and
adipose tissue is important, especially in humans. However, no
previous studies have demonstrated the association among these
organs comprehensively and simultaneously [14,15]. In addition,
liver biopsy remains gold standard for diagnosis of NAFLD
because it more accurately measures liver fat than proton
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magnetic resonance spectroscopy (1H-MRS) under some condi-
tions [16].
The present study try to address the association of organ-specific
IR with ectopic fat among the liver, skeletal muscle, and adipose
tissue in Japanese patients with NAFLD, systematically using
reliable methods including liver biopsy, assessment of glucose
metabolism measured by a euglycemic hyperinsulinemic clamp
study with stable-isotope, and 1H-MRS.
Materials and Methods
Ethics Statement
The study was approved by the Medical Ethics Committee of
Kanazawa University (Approval No. 845), and written informed
consent was obtained from each patient prior to participation. The
study was conducted in accordance with the Declaration of
Helsinki.
Participants and Study Design
We studied 69 patients clinically diagnosed with NAFLD,
recruited consecutively between 2010 and 2012 from Kanazawa
University Hospital, Japan. The patients were in good general
health without evidence of any acute or chronic diseases (other
than NAFLD, T2DM, hypertension, or dyslipidemia) as deter-
mined by history, physical examination, routine blood chemistries,
urinalysis, and electrocardiography. Out of the 69 patients, 37
(54%) had T2DM according to the American Diabetes Association
criteria. Of the 37 T2DM patients, antidiabetic agents were
administered to 18 patients in monotherapy and 7 patients in
combination therapy (metformin, n= 15; dipeptidyl peptidase-4
inhibitors, n = 9; glucagon-like peptide-1 agonists, n = 7; mealtime
dosing of a rapid-acting insulin analog, n= 5, respectively). None
of the patients were taking a-glucosidase inhibitors, rapid-acting
insulin secretion agents, sulfonylurea, thiazolidinediones, or long-
acting insulin. Participants were excluded if they had a history of
alcohol abuse (more than 20 g/day), liver diseases other than
NAFLD (hepatitis B or C, autoimmune hepatitis, hemochroma-
tosis, Wilson disease, drug-induced disease, or other), type 1
diabetes, or a history of clinically significant renal, pulmonary, or
heart diseases.
The participants were studied on four separate occasions.
Generally, all measurements were performed within 1 month and
included: 1) organ-specific IR in the liver, skeletal muscle, and
adipose tissue by a euglycemic hyperinsulinemic clamp study with
tracer ([6,6-2H2]glucose) infusion; 2) liver biopsy for histology to
confirm the diagnosis of NAFLD and score the degree of steatosis,
grade, and stage; 3) intrahepatic lipid (IHL) and intramyocellular
lipid (IMCL) measured by 1H-MRS, and body composition by a
bioelectrical impedance analysis; and 4) 75-g oral glucose
tolerance test (OGTT) to evaluate the glucose tolerance according
to American Diabetes Association criteria [17].
Euglycemic Hyperinsulinemic Clamp
After an overnight fast, two intravenous catheters, one for blood
sampling and one for infusion of glucose, insulin, and tracers, were
inserted in the antecubital vein of each arm. At 0700 h, after
obtaining a blood sample for background enrichment of plasma
glucose, a continuous infusion of [6,6-2H2]glucose (.99%
enriched; Cambridge Isotope, Andover, MA, USA) was started
at a rate of 0.05 mg?kg21?min21 after a priming dose equivalent.
After 100, 110, and 120 min, blood samples were obtained for
determination of tracer enrichments. Subsequently, at 0900 h, the
euglycemic hyperinsulinemic clamp study was started using an
artificial pancreas (model STG-55; Nikkiso, Tokyo, Japan), as
described previously [18,19]. A primed continuous infusion of
insulin (Humulin R; Eli Lilly, Indianapolis, IN, USA) was started
for 2.0 h at a rate of 1.25 mU?kg21?min21 to attain a plasma
insulin concentration of approximately 100 mU/mL. Glucose was
infused to maintain a plasma glucose concentration of 100 mg/dL
(or 90 mg/dL for baseline values under 90 mg/dL). Simulta-
neously, [6,6-2H2]glucose infusion was continued at a rate of
0.15 mg?kg21?min21. During the last 20 min of the clamp study,
blood samples were obtained in 10-min intervals to determine
tracer enrichments.
Liver Biopsy/Pathology
Ultrasound-guided liver biopsy specimens were obtained from
all 69 patients. Each specimen was stained with hematoxylin-eosin
and silver reticulin stains and histologically examined by one
experienced pathologist who was blinded to the patient’s clinical
condition and biochemical data. The biopsied tissues were scored
for steatosis (0, none; 1, ,33%; 2, 33–66%; 3, .66%), stage, and
grade as described previously (10), according to the standard
criteria for grading and staging of nonalcoholic steatohepatitis
proposed by Brunt et al. [20,21].
Liver Fat Content and IMCL (Proton Magnetic Resonance
Spectroscopy)
IHL and IMCL were measured as reported previously [22,23].
Briefly, IHL of the liver’s right lobe and IMCL of the soleus
muscle were measured by 1H-MRS using a whole-body 3.0 T MR
System (Signa HDxt 3.0 T, General Electric Healthcare,
Milwaukee, WI, USA). Voxels (3.063.063.0 cm3 for liver and
2.062.062.0 cm3 for soleus muscle) were positioned in the liver or
soleus muscle to avoid blood vessels and visible interfacial fat, and
the voxel sites were carefully matched at each examination.
Imaging parameters were set to repetition time of 1500 ms and
echo time of 27 ms. To quantify IHL and IMCL, the MR spectral
raw data were processed by using the LCModel software (Version
6.3-0C, Stephen Provencher, Oakville, Ontario, Canada).
Body Composition
Body composition, such as fat mass and fat-free mass, was
determined by a bioelectrical impedance analysis (Tanita BC-
118D, Tanita, Tokyo, Japan).
Oxygen Consumption
Oxygen consumption was measured using indirect calorimetry
(Aeromonitor AE310S, Minato, Osaka, Japan).
75-g OGTT
After an overnight fast, a 75-g OGTT was performed at 0800 h.
Blood samples were collected at 0, 30, 60, 90, 120, and 180 min to
measure plasma glucose insulin and C-peptide concentrations.
Analytical Methods
Plasma glucose was measured by the glucose oxidase method
(Glucose Analyzer GA09; A&T, Kanagawa, Japan), and plasma
insulin and C-peptide were measured using a sandwich enzyme
immunoassay system with E-test Tosoh II (IRI) and E-test Tosoh
II (C-peptide) (Tosoh, Tokyo, Japan). Plasma FFA was measured
by a standard colorimetric method using NEFA-SS (Eiken, Tokyo,
Japan). Hemoglobin A1c level was measured using high-perfor-
mance liquid chromatography (TOSOH HLC-723G8; Tosoh,
Tokyo, Japan).
Deuterated glucose was analyzed as a penta-acetate derivative
using the method by Wolfe [24]. Samples were analyzed on a
Ectopic Fat and Distant Organ Insulin Resistance
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quadrupole gas chromatography mass spectrometry instrument
(GCMS-QP1100EX, Shimadzu, Kyoto, Japan) operated in the
electron impact mode by selective-ion monitoring of m/z 200,
201, and 202. Oven temperature was 180uC with a 10uC/min rate
of temperature rise until 250uC with a 25 m HR-1 capillary
column (Shinwa Chemical Industries, Kyoto, Japan). Tracer
concentrations were calculated based on the sample’s tracer-to-
tracee mass ratio [25].
Calculations
In the basal state, hepatic glucose production (HGP) was
calculated as the rate of appearance (Ra) of glucose according to
the Steele’s equation as previously described [19,26]. During the
clamp study, glucose Ra was calculated using Steele’s equation
from tracer data [26]. HGP during the clamp study was calculated
as the difference between glucose Ra and the infusion rate of
exogenous glucose.
We calculated and defined organ-specific IR in the liver, skeletal
muscle, and adipose tissue as described previously [27–30].
Hepatic IR indices were calculated as the product of fasting
HGP and fasting plasma insulin (FPI) concentration (HGP6FPI
[(mg?kg21?min21)6(mU/mL)]) and suppression of HGP by insulin
during a clamp study (%HGP). The skeletal muscle IR index was
calculated as insulin-stimulated glucose disposal (Rd), and the
adipose tissue IR index was calculated as suppression of FFA by
insulin during a clamp study (%FFA).
Statistical Analysis
All analyses were performed using SPSS software version 21.0
(SPSS Inc., Chicago, IL, USA). All values are expressed as mean
6 SEM, unless stated otherwise. The relationship between
individual variables was assessed by Pearson’s correlation for
parametric variables and by Spearman’s correlation for non-
parametric variables. Multiple linear regression analysis was used
to assess independent determinants of organ-specific IR. The
differences between the two groups were assessed by Student’s t-
test for continuous variables and chi-square test for categorical
variables. Data involving more than two groups were assessed by
analysis of variance (ANOVA). Statistical significance was
considered to be P,0.05.
Results
Organ-specific IR and Clinical Characteristics in Patients
with NAFLD
The characteristics of the study subjects and their metabolic
profiles are shown in Table 1. During the clamp study, plasma
glucose concentrations were maintained at baseline values
(10361 mg/dL; mean 6 SEM), and steady-state plasma insulin
concentrations were reached at 110.263.6 mU/mL. Basal HGP
was 2.0960.08 mg?kg21?min21 in subjects with normal glucose
tolerance (NGT), 2.1860.10 mg?kg21?min21 in subjects with
impaired glucose tolerance (IGT) and 2.6760.12 mg?kg21?min21
in subjects with T2DM. Rd was 3.8160.18 mg?kg21?min21 in
NGT, 3.2760.17 mg?kg21?min21 in IGT and
3.5760.14 mg?kg21?min21 in T2DM. Basal FFA was
0.4760.05 mEq/L in NGT, 0.5660.04 mEq/L in IGT and
0.6060.04 mEq/L in T2DM. Basal HGP showed a significant
positive correlation with fasting plasma glucose levels (r=0.48, P,
0.001). Rd showed a significant positive correlation with basal
oxygen consumption rate per body weight (VO2) (r=0.42, P,
0.01). FFA and HGP were suppressed from baseline by
77.061.4% and 69.362.8%, respectively. These values are similar
to previous data in Japanese [31] and European descent [1,27,29]
subjects.
The relationship between clinical characteristics and organ-
specific insulin sensitivity/resistance indices is shown in Table 2.
HGP6FPI was significantly correlated with Rd (r=20.57, P,
0.001), %HGP with %FFA (r=0.38, P,0.01), and Rd with %FFA
(r=0.27, P,0.05) suggesting that the IRs in the liver, skeletal
muscle, and adipose tissue were significantly associated with each
other, although the correlation was not very strong.
Ectopic Fat and Organ-specific IR
Histological liver steatosis score was strongly correlated with
IHL measured by 1H-MRS (r = 0.75, P,0.001).
Liver steatosis score was significantly correlated with Rd (r=2
0.47, P,0.001) as well as HGP6FPI (r = 0.43, P,0.001) (Table 2).
Similarly, IHL was significantly correlated with Rd (r=20.32, P,
0.05) and tended to be correlated with HGP6FPI (r = 0.25,
P=0.09) (Figure 1A, 1B). In the multiple regression analysis, liver
steatosis score was significantly correlated with both HGP6FPI
(b=0.284, P,0.05) and Rd (b=20.300, P,0.01) after adjusting
for age, sex, and BMI. Correlation of liver steatosis score with Rd
(b=20.261, P,0.05) was significant after further adjusting for
total fat mass (Table 3). When stratified by steatosis score,
HGP6FPI was significantly higher and Rd was significantly lower
in the score 3 steatosis group compared to the score 0 steatosis
group (P,0.01; P,0.001, respectively) (Figure 1C,1D).
Unexpectedly, indices of fat accumulation in the skeletal muscle
(IMCL) and adipose tissue were not associated with their own
organ-specific IR (Table 2). IMCL and fat-free mass were not
correlated with Rd (r=20.16, P=0.26; r=20.22, P=0.08,
respectively) (Figure 2A,2B). Total fat mass and its percentage
were correlated with HGP6FPI (r = 0.50, P,0.001; r = 0.48, P,
0.001, respectively) and Rd (r=20.59, P,0.001; r=20.52, P,
0.001, respectively), but not with %FFA (r=20.21, P=0.10; r=2
0.00, P=0.99, respectively) (Figure 2C,2D).
Similar results were obtained when Rd was normalized by
steady state plasma insulin (Rd/SSPI) (Table 2).
Because it may be possible that T2DM itself is associated with
IR independently with organ steatosis, we analyzed the subjects
with or without T2DM. Age, hemoglobin A1c, fasting plasma
glucose, 2-h glucose level of 75-g OGTT and basal HGP were
significantly higher in T2DM group compared to non-DM group
(Table 1). Regardless of the presence or absence of T2DM, liver
steatosis score was significantly correlated with Rd as well as
HGP6FPI, and IMCL and total fat mass were not correlated with
Rd or %FFA respectively (Table 4, Table 5). The results of the
multiple regression analysis are shown in Table S1 and Table S2.
Discussion
We comprehensively and simultaneously evaluated ectopic fat
accumulation and organ-specific IR in insulin-target organs in
Japanese people with NAFLD, and found the following: 1) the IRs
in the liver, skeletal muscle, and adipose tissue were associated
with each other, 2) indices of fat accumulation in the skeletal
muscle and adipose tissue were not associated with their own
organ-specific IR, and 3) liver fat was associated with skeletal
muscle IR as well as hepatic IR, independently of age, sex, BMI
and total fat mass (Figure S1).
Although the IRs in the liver, skeletal muscle, and adipose tissue
were associated with each other, the relation was relatively weak.
There are a couple possible explanations for this result. First, the
main site and the severity of IR may vary among organs and
individuals [4]. Second, possibly the %HGP and %FFA are not
Ectopic Fat and Distant Organ Insulin Resistance
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completely suitable for indices of hepatic and adipose tissue IR,
respectively, and might not fully exhibit inter-individual variation
because HGP and lipolysis appeared to be more sensitive to
suppression by insulin compared to stimulation of Rd by insulin
Table 1. Clinical characteristics of the study subjects.
All non-DM (NGT+IGT) T2DM P value*
n 69 32 37
Age (years) 5162 4663 5562 0.008b
Sex (Male/Female) 42/27 23/9 19/18 0.082
Body mass index (kg/m2) 30.360.9 30.961.2 29.861.4 0.526
Weight (kg) 82.362.7 86.563.8 78.663.9 0.152
Fat-free mass (kg) 50.261.3 52.761.6 47.961.9 0.058
Total fat mass (kg) 30.662.0 31.062.9 30.262.9 0.855
Body fat percentage (%) 36.361.3 35.661.9 37.061.8 0.594
Historogical scores
Steatosis (0/1/2/3) 5/33/15/16 4/13/5/10 1/20/10/6
Grade (0/1/2/3) 15/35/16/3 10/14/7/1 5/21/9/2
Stage (0/1/2/3/4) 20/29/6/11/3 12/14/1/4/1 8/15/5/7/2
NAFLD activity score (0/1/2/3/4/5/6/7/8) 3/5/12/14/12/9/13/1/0 2/4/4/7/4/5/5/1/0 1/1/8/7/8/4/8/0/0
IHL (mmol/L) 9.6361.01 7.3061.27 11.2361.41 0.056
IMCL (AU, ratio relative to creatine) 28.2961.49 27.9162.21 28.5862.04 0.827
Glucose tolerance (NGT/IGT/DM) 11/21/37
Hemoglobin A1C (%) 6.560.1 6.060.1 7.060.1 ,0.001c
Fasting plasma glucose (mg/dL) 11162 10062 12163 ,0.001c
2-h glucose (mg/dL) 208610 14266 265612 ,0.001c
Fasting plasma insulin (mU/mL) 14.061.0 15.161.5 13.161.3 0.318
2-h insulin (mU/mL) 139.1612.6 157.2621.8 123.5613.7 0.182
Insulinogenic index [(mU/mL)/(mg/dL)] 0.7260.09 0.9560.16 0.5260.09 0.019a
Fasting C-peptide (ng/mL) 2.960.1 3.160.2 2.760.2 0.199
Fasting FFAs (mEq/L) 0.5760.03 0.5360.03 0.6060.04 0.254
Total cholesterol (mg/dL) 17664 18566 16966 0.061
Triglycerides (mg/dL) 153611 150610 155618 0.801
HDL cholesterol (mg/dL) 4161 4162 4162 0.927
Aspartate aminotransferase (IU/L) 3762 3763 3763 0.969
Alanine aminotransferase (IU/L) 6064 6266 5965 0.752
Basal HGP (mg?kg21?min21) 2.4360.08 2.1560.07 2.6760.12 0.001b
HGP6FPI [(mg?kg21?min21)6(mU/mL)] 32.062.0 31.262.8 32.762.9 0.707
Euglycemic hyperinsulinemic clamp [clamp period]
Clamped glucose (mg/dL) 10361 10262 10462 0.592
Steady state plasma insulin (mU/mL) 110.263.6 115.766.0 105.364.2 0.164
FFAs (mEq/L) 0.1360.01 0.1360.01 0.1360.01 0.884
%FFA (%) 77.061.4 75.962.0 78.061.9 0.455
HGP (mg?kg21?min21) 0.6960.07 0.5660.07 0.8160.12 0.088
%HGP (%) 69.362.8 73.463.5 65.864.1 0.170
Rd (mg?kg21?min21) 3.5260.10 3.4560.14 3.5760.14 0.556
Rd/SSPI [(mg?kg21?min21)/(mU/mL)] 0.03560.002 0.03360.003 0.03760.003 0.332
VO2 (ml?kg
21?min21) 2.8560.04 2.8460.07 2.8660.06 0.817
Data are presented as n or mean 6 SEM.
IHL, intrahepatic lipid; IMCL, intramyocellular lipid; AU, arbitrary units; HGP, hepatic glucose production; FPI, fasting plasma insulin; SSPI, steady state plasma insulin; VO2,
basal oxygen consumption rate per body weight.
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Figure 1. Correlation between liver fat and organ-specific insulin resistance (IR). (A) univariate correlation between IR in the liver
(HGP6FPI) and liver fat (IHL) (r = 0.25, P= 0.09). (B) univariate correlation between skeletal muscle IR index (Rd) and liver fat (IHL) (r=20.32, P,0.05).
(C) IR in the liver (HGP6FPI) stratified by steatosis score. (D) skeletal muscle IR index (Rd) stratified by steatosis score. *P,0.05 vs. score 0 steatosis
group. **P,0.01 vs. score 0 steatosis group.
doi:10.1371/journal.pone.0092170.g001
Table 3. Multiple regression models predicting HGP6FPI and Rd.
HGP6FPI Rd
b P b P
Steatosis (Model 1) 0.284 0.026a 20.300 0.007b
Steatosis (Model 2) 0.216 0.098 20.261 0.027a
HGP, hepatic glucose production; FPI, fasting plasma insulin.
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[32,33]. Lowering steady-state insulin levels by a reduced insulin
infusion rate might improve the specificity of these indices to
reflect organ insulin sensitivity.
In the present study, IMCL was not associated with skeletal
muscle IR. The participants in this study had a wide BMI range
(21.3–54.9 kg/m2) and subjects may have different physical
exercise habits with various intensities. IMCL is increased not
only by obesity but also by enhanced physical fitness [34].
Therefore, absolute fat contents do not always predict IR in the
skeletal muscle, thus, toxic lipids that cause IR in the skeletal
muscle should be further researched. Similarly, we failed to find
any relationship between fat mass or its percentage and adipose
tissue IR. Although we evaluated only total fat mass, distribution
of adipose tissue may potentially determine insulin action. Indeed,
visceral fat, but not subcutaneous fat, is reported to be associated
with %FFA [35]. Therefore, future studies should evaluate visceral
and subcutaneous fat masses separately and evaluate the relation
to %FFA in Japanese people.
In addition to the previously well-recognized relationship
between adipose tissue mass and IR in the liver and skeletal
muscle [36], the present study showed a distinct relationship
between liver fat and skeletal muscle IR independently of age, sex,
and BMI. Although our results are consistent with previous studies
showing that liver fat plays an important role in peripheral IR as
well as hepatic IR [14,15], not all associations among components
of ectopic fat and organ-specific IR were examined simultaneously
in these studies. Our findings suggest that hepatic steatosis per se is
a central surrogate pathology indicative of IR in both liver and
Figure 2. Correlation between ectopic fat and organ-specific insulin resistance (IR). (A) univariate correlation between skeletal muscle IR
index (Rd) and intramyocellular lipid (IMCL) (r=20.16, P= 0.26). (B) univariate correlation between Rd and fat-free mass (r = 0.22, P= 0.08). (C)
univariate correlation between adipose tissue IR index (%FFA) and total fat mass (r=20.21, P=0.10). (D) univariate correlation between %FFA and
body fat percentage (r=20.00, P= 0.99).
doi:10.1371/journal.pone.0092170.g002
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skeletal muscle in patients with NAFLD. In addition, there may be
a network between the liver and skeletal muscle to maintain whole
body energy homeostasis. Accordingly, whether hepatic steatosis is
a consequence or cause of skeletal muscle IR remains uncertain
because a longitudinal observation of the relationship is lacking.
One hypothesis is that skeletal muscle IR causes obesity and
subsequent hepatic steatosis as experimentally shown in mice with
muscle-selective IR [37]. Indeed, Flannery et al. recently reported
that skeletal muscle IR promotes increased hepatic de novo
lipogenesis and hepatic steatosis in the elderly [38]. A second
hypothesis is the neuronal pathway from the liver might modulate
peripheral insulin sensitivity [11]. A third hypothesis is that some
nutrients, such as fatty acids and amino acids, might link hepatic
steatosis and skeletal muscle IR [39]. A fourth hypothesis is that a
liver-derived hormone (a hepatokine) affects the distant organ
insulin sensitivity. We previously isolated hepatokine selenoprotein
P, which is overproduced under an overnutrition state and causes
IR both in the liver and skeletal muscle [13]. In addition, serum
levels of selenoprotein P are inversely associated with serum levels
of adiponectin [40] that enhance skeletal muscle insulin sensitivity
[12]. Therefore, overproduction of selenoprotein P in association
with hepatic steatosis, by directly or indirectly lowering adipo-
nectin levels, causes skeletal muscle IR.
There are several limitations to this study. First, this was an
observational study, and we were unable to examine causal
associations. A large-scale longitudinal study is needed to clarify
whether hepatic steatosis is a consequence or cause of skeletal
muscle IR. Second, many of the study subjects had glucose
intolerance/diabetes, although the severity was relatively mild as
shown by the OGTT. Therefore, IR of each organ was possibly
greater in our study subjects than in the general population, which
could have influenced the results. Third, fifteen out of 69 subjects
were taking metformin which might influence hepatic glucose
production. However, major study results were similar in diabetic
subjects, non-diabetic subjects, and subjects without metformin
(data not shown). Fourth, we did not collect arterial or arterialized
blood samples to perform the insulin clamp because these were not
included in the manufacturer’s protocol of the artificial pancreas
model STG-55. Further study should be required to confirm our
conclusion by using arterial or arterialized blood samples.
In summary, the present study revealed an unexpected lack of
an association between fat and local organ-specific IR in the
skeletal muscle and adipose tissue. Instead, liver fat is strongly
associated with skeletal muscle IR as well as with liver IR,
suggesting a central role of fatty liver in the development of IR and
that a network exists between liver and skeletal muscle to maintain
whole-body energy homeostasis.
Supporting Information
Figure S1 Correlation between ectopic fat and insulin
resistance (IR) in the liver, skeletal muscle, and adipose
tissue. Liver fat (steatosis score) was associated with skeletal
muscle IR index (Rd) as well as with IR in the liver (HGP6FPI).
Intramyocellular lipid was not associated with skeletal muscle IR
index (Rd). Total fat mass was associated with HGP6FPI and Rd,
but not with adipose tissue IR index (%FFA).
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Table S1 Multiple regression models predicting
HGP6FPI and Rd in subjects without type 2 diabetes
(n=32). HGP, hepatic glucose production; FPI, fasting plasma
insulin Model 1, adjusted for, age, sex, and body mass index;
Model 2, adjusted for, age, sex, body mass index, and total fat
mass.
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Table S2 Multiple regression models predicting
HGP6FPI and Rd in subjects with type 2 diabetes
(n=37). HGP, hepatic glucose production; FPI, fasting plasma
insulin Model 1, adjusted for, age, sex, and body mass index;
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